User:Mr. Ibrahem/Belumosudil

Belumosudil, sold under the brand name Rezurock among others, is a medication used to treat chronic graft versus host disease (cGvHD). It is used in those who are at least 12 years of age who do not improve after other treatments. It is taken by mouth.

Common side effects include infections, weakness, nausea, diarrhea, shortness of breath, cough, swelling, bleeding, abdominal pain, musculoskeletal pain, headache, low phosphate, low lymphocytes, and high blood pressure. Use in pregnancy may harm the baby. It is a kinase inhibitor; specifically of Rho-associated coiled-coil kinase 2 (ROCK2).

Belumosudil was approved for medical use in the United States in 2021. While it is approved in the United Kingdom, it is not in the rest of Europe as of 2022. In the United States it costs about 17,000 USD per month as of 2022. In the UK, a one month supply costs the NHS around £6,700 as of 2023.